TVTX - Travere Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart

TVTX is currently covered by 11 analysts with an average price target of $59.85. This is a potential upside of $12.85 (27.34%) from yesterday's end of day stock price of $47.

Our record on Travere Therapeutics covers 22 analysts since 2008; 11 cover it today. Of the 195 price targets those analysts set on TVTX, 181 were reached (93%). The highest performance score on Travere Therapeutics belongs to Anupam Rama of JPMorgan: 7.44, with 6 of 6 targets met in 316 days on average. The latest calls: Vamil Divan of Guggenheim cut the target to $78 from $89 with a Buy rating on 4 Nov 2026; Laura Chico of Wedbush raised the target to $76 from $75 with a Buy rating on 22 Sep 2026; Joseph Pantginis of H.C. Wainwright kept the target at $67 with a Buy rating on 22 Sep 2026. Figures as of 18 Nov 2026.

Travere Therapeutics's activity chart (see below) currently has 253 price targets and 205 ratings on display. The stock rating distribution of TVTX is 91.43% BUY and 8.57% HOLD.

Stock Analyst Price Targets - Review

Analysts' price targets on this stock were met 94.21% of the time, taking 487.54 days on average.

Highest price target for TVTX is $85, Lowest price target is $38, average price target is $59.85.

Most recent stock forecast was given by VAMIL DIVAN from GUGGENHEIM on 04-Nov-2026. First documented stock forecast 23-Nov-2020.

Best performing analysts who are covering TVTX - Travere Therapeutics:

Michelle Gilson Joseph Pantginis Edward Nash Joseph Schwartz Vamil Divan Do Kim

Currently out of the existing stock ratings of TVTX, 32 are a BUY (91.43%), 3 are a HOLD (8.57%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 27-Sep-2024

$78

$31 (65.96%)

$89

17 days ago
(04-Nov-2026)

11/14 (78.57%)

$25.58 (48.80%)

434

Buy Since 17-Apr-2023

$76

$29 (61.70%)

$75

1 months 30 days ago
(22-Sep-2026)

20/22 (90.91%)

$15.72 (26.08%)

323

Buy Since 01-Jul-2025

$67

$20 (42.55%)

$67

1 months 30 days ago
(22-Sep-2026)

9/10 (90%)

$6.72 (11.15%)

170

Buy Since 16-Feb-2024

$85

$38 (80.85%)

$70

3 months 16 days ago
(05-Aug-2026)

4/6 (66.67%)

$22.24 (35.44%)

98

Buy Since 22-May-2023

$75

$28 (59.57%)

$60

3 months 16 days ago
(05-Aug-2026)

9/10 (90%)

$12.24 (19.50%)

281

Show more analysts

Please expand the browser size to see the chart

What is TVTX (Travere Therapeutics) average time for price targets to be met?

On average it took 488 days for the stock forecasts to be reached, with an average price target met ratio of 94.21%.

Which analyst most recently updated their price target on TVTX (Travere Therapeutics)?

Vamil Divan

Which analyst has the most public recommendations on TVTX (Travere Therapeutics)?

Vamil Divan works at GUGGENHEIM and has 2 price targets and 2 ratings on TVTX

Which analyst is the currently most bullish on TVTX (Travere Therapeutics)?

Yigal Nochomovitz with the highest potential upside of $38

Which analyst is the currently most reserved on TVTX (Travere Therapeutics)?

Nicole Gabreski with the lowest potential downside of -$46.85
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?